Global Pharma Labs, Inc. is a pharmaceutical company focused on developing effective low-priced medication treatments of diseases affecting humans.
Pharmaceutical San Leandro, CA https://www.globalpharmalabs.net/
GPL is a biopharmaceutical company dedicated to developing solutions to disease
processes in human patients. GPL’s goal is to establish a portfolio of patents with supporting
data in humans for treatment of various diseases; to manufacture these various treatments;
and to bring such treatments to the global market place.
To this end we have already obtained exclusive rights to the patented first disease
modifying prescription medication therapy for osteoarthritis (OA), a disease affecting an
estimated 21 million to 55 million people in the U.S. alone and around 750 million people
globally – expanding at 7 – 10% annually as the population ages.
Osteoarthritis is the most prevalent form of arthritis and the second most prevalent
pharmaceutical market. The current US market for all OA treatments is around $15 billion per
year and growing. In addition the disease is currently undertreated, as present recommended
medical treatments have safety concerns and essentially treat only the pain symptom and not
the disease itself.
GPL’s immediate goal is to substantiate in human patients the efficacy and safety of our already
patented disease‐modifying therapy to treat arthritic disease, inclusive of osteoarthritis (OA)
which is the most common arthritic disease among humans. This treatment is based on a
series of issued patents for a triple combination of already FDA approved antimicrobial drugs
that are generically available today. This GPL product (“OA‐sys”) WILL PROVIDE PATIENTS
FAST ACTING DISEASE MODIFYING THERAPY LEADING TO LONG TERM PAIN RELIEF.
Osteoarthritis is one of the most common diseases in the geriatric population, affecting
as much as 80% of the population over 65 years of age, and is a leading cause of permanent
disability, incapacity and pain. In addition to its disease‐modifying benefits, there is significant
opportunity for OA‐sys, with its long‐established safety profile, to fill the void in the OA
marketplace. Competitive products are marketed for transient pain relief only and many of
those products used to treat arthritic pain are contraindicated in OA patients. Vioxx and Bextra
have been withdrawn from the market. Ibuprofen, Naproxen and Celebrex are often
contraindicated in the elderly due to the potential for cardiovascular and stroke events.
The long history of the three separately approved drugs that make up OA‐sys minimizes
the risks associated with products development. In addition, the safety profiles are well
documented. These factors will help to facilitate a rapid path to completion of clinical trials.
The clinical pilot studies have already been completed wherein OA‐sys was administered
orally twice daily for eight weeks to OA patients. The combination product was successful in
substantially reducing joint pain, tenderness, and stiffness while decreasing fatigue and
increasing both energy and function. The proof of concept study treatment with OA resulted in
mean improvement in Pain (90.1%), Stiffness (94.5%) and Functional Limitations (86.5%)
respectively. The results indicate the product is capable of eliminating or markedly diminishing
the OA symptomatology with a concomitant elimination or decrease the need for analgesic
medications and negligible side effects. These results form the basis for the clinical
development of OA‐sys.
A businessman with experience in real estate development of
residential care homes for seniors, foster kids and mentally disabled. He owned and operated a Mortgage Company which focused on Commercial Financing as well as Residential loans.
Currently he provides management for physician practices.
Kuo Liang is a California licensed pharmacist for 40 years. During that time he worked for Merrit and Kaiser Hospitals and has owned and operated two pharmacies.
Offering 40,000,000 shares at $1.00 per share, or $40,000,000. Common stock outstanding before the offering: 50,500,000.
We are a pre-clinical stage biopharmaceutical company with a limited operating history. Since inception, we have focused our efforts primarily on developing OA-sys, with the goal of achieving regulatory approval. Since inception, we have incurred operating losses. To date, we have not received regulatory approvals for any of our product candidates or generated any revenue from the sale of products, and we do not expect to generate any revenue in the foreseeable future. We expect to continue to incur substantial and increasing expenses and operating losses over the next several years, as we continue to develop OA-sys, and our other current and future product candidates. In addition, we expect to incur significant sales, marketing, and manufacturing expenses related to the commercialization of OA-sys, and our other current and future product candidates, if they are approved by the U.S. Food and Drug Administration (“FDA”) or such an equivalent in any other jurisdiction. As a result, we expect to continue to incur significant losses for the foreseeable future.
For more risk specific to our company please read the offering circular.
CrowdVest shall be entitled to receive an administration fee of $5,000 per month from GPL that will be due upon completion of the offering. The fee does not depend on the size of the offering or its success. In addition, CrowdVest shall be entitled to receive the equivalent of $100,000 dollars in shares and $100,000 dollars in warrants.